- Voyager Therapeutics ( NASDAQ: VYGR ) said it will get $10M after Pfizer ( NYSE: PFE ) exercised an option to license a adeno-associated virus (AAV) capsid for a potential gene therapy program for a rare neurologic disease target.
- AAV capsids are a type of delivery vehicles for gene therapies.
- Under the license option agreement, announced in October 2021, Voyager previously received $30M upfront and was entitled to receive $10M on option exercise. Voyager is also eligible to receive potential future development, regulatory and commercialization milestones of up to $290M, plus royalties.
- Voyager said in an Oct. 4 press release that Pfizer elected not to exercise its option to license a capsid for the cardiac target under the original agreement, and all capsid rights for that target are returned to Voyager.
- Voyager retains global rights to all licensed capsids for use with other transgenes and to all other applications of its TRACER technology,
- VYGR +6.57% to $6 premarket
For further details see:
Voyager stock rises as Pfizer opts to use AAV capsid for neurologic disease target